Trastuzumab

Red

Brand Name(s):Herceptin
Ontruzant
Herzuma
Kanjinti

Indication:HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction

Rationale:1,2,3

Considered:Mar-10

Review Date:Jun-23

Comments:
NICE TA632 – Trastuzumab emtansine is recommended, as an option for adjuvant treatment of HER2+ve early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2 targeted therapy.

NICE TA 208
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
November 2010